Autophagic vacuolar cardiomyopathy is an underrecognized, but potentially fatal, complication of treatment with chloroquine (CQ) and its derivative hydroxychloroquine (HCQ), which are used as therapy for malaria and common connective tissue disorders. Currently, the diagnosis of autophagic vacuolar cardiomyopathy is established through an endomyocardial biopsy and requires electron microscopy, which is not widely available and has a significant potential for sampling error. Recently, we have reported that immunohistochemistry for autophagic markers LC3 and p62 can replace electron microscopy in the diagnosis of HCQ-induced and colchicine-induced autophagic vacuolar skeletal myopathies. In the current study, we use 3 cases of CQ-induced or HCQ-induced cardiomyopathy and 1 HCQ-treated control case to show that the same two markers can be used to diagnose autophagic vacuolar cardiomyopathies by light microscopy. CQ-induced or HCQinduced autophagic vacuolar cardiomyopathy is not universally fatal, but successful treatment requires early detection. By lowering the barriers to diagnosis, the application of these immunohistochemical markers will decrease the number of misdiagnosed patients, thus increasing the likelihood of favorable clinical outcomes.
C hloroquine (CQ) and its derivative hydroxychloroquine (HCQ) are 4-aminoquinoline compounds that are commonly used for the prevention and/or treatment of malaria and connective tissue disorders such as rheumatoid arthritis and lupus erythematosus. 1 Overall, these drugs have a favorable side-effect and safety profile; however, development of an autophagic vacuolar cardiomyopathy is an insufficiently recognized, but potentially fatal, complication of CQ or HCQ treatment.
The existing literature on CQ-induced and HCQinduced cardiomyopathy mostly consists of single-case or double-case reports; on the basis of a 2007 summary, 2 11 cases of HCQ cardiotoxicity, 40 cases of CQ cardiotoxicity, and 3 cases of combined HCQ and CQ cardiotoxicity were reported up to that point. Interestingly, the treatment duration and cumulative drug dosage for reported cases spanned months to years of treatment and hundreds to thousands of grams of drug consumed, 2 suggesting that other factors (such as genetic predisposition and/or presence of comorbid diseases) play a role in the development of aminoquinoline-induced cardiomyopathy. HCQ is thought to have a more favorable side-effect profile than CQ; however, its increased use may lead to a rise in the number of cases of HCQ-induced toxicity. 2, 3 Both CQ and HCQ accumulate within lysosomes, resulting in lysosomal alkalization 1 and inhibition of lysosomal hydrolytic enzymes; the resulting block in the processing of key immune regulators is thought to lead to the desired anti-inflammatory effects. 4 However, the concomitant inhibition of macroautophagy (a catabolic process constitutively active in all cell types) can lead to the accumulation of cellular debris and misfolded protein aggregates. 5 The abnormal accumulation of insufficiently degraded cellular components in cardiac myocytes can culminate in autophagic vacuolar cardiomyopathy, which clinically manifests with symptoms of chronic heart failure, conduction disorders, and/or restrictive cardiomyopathy. 2, 3, 6 The diagnosis of autophagic vacuolar cardiomyopathy is generally established through an endomyocardial biopsy; however, routine histology shows primarily cardiomyocyte vacuolation that can be misinterpreted as a nonspecific change or an artifact, particularly when the relevant clinical information regarding CQ or HCQ use is lacking. The specific diagnosis can be made through ultrastructural analysis, which shows frequent autophagic vacuoles with myelin figures (seen in all autophagic myopathies) and/or curvilinear bodies (which are relatively specific for CQ and HCQ toxicity) 1,2,7-9 ; however, the utility of electron microscopy is limited by the special tissue handling requirements, unavailability of electron microscopes in smaller pathology laboratories, relatively long turn-around time, and significant possibility of a sampling error. Hence, the development of a fast and relatively inexpensive immunohistochemical test for autophagic vacuolar cardiomyopathy, which could be performed on any endomyocardial biopsy that shows vacuolar changes, would decrease the number of misdiagnosed cases and thus significantly improve the expected patient outcomes.
Recently, we have reported that immunohistochemistry for autophagic markers LC3 and p62 can replace electron microscopy in the diagnosis of HCQinduced and colchicine-induced autophagic vacuolar skeletal myopathies. 7 Here, we use 3 cases of CQ-induced or HCQ-induced autophagic vacuolar cardiomyopathy and 1 HCQ-treated control case to show that the same two markers can be used to diagnose autophagic vacuolar cardiomyopathies by light microscopy.
MATERIALS AND METHODS

Clinicopathologic Evaluation
Clinical history, physical examination findings, laboratory and imaging reports, and surgical and autopsy pathology reports were obtained from outpatient and inpatient medical records of Vanderbilt University Medical Center (patient 1), Oregon Health and Science University (patient 2), and University of Nebraska Medical Center (UNMC) (patients 3 and 4). The permission to use tissue for research was covered by autopsy permits signed by the next-of-kin for patients 2, 3, and 4; for patient 1, Vanderbilt University Institutional Review Board waived the informed consent requirement given a minimal potential for harm. No individually identifiable patient data are presented in this report.
Procedures
Electron Microscopy
Ultrathin (80 nm) sections of the glutaraldehydefixed, Epon-embedded tissue were stained with 2% uranyl acetate. Sections were examined in an FEI Morgagni transmission electron microscope at 60 kV (patient 1) or 70 kV (patient 2) or in a JEOL 1230 transmission electron microscope at 60 kV (patients 3 and 4). Images were obtained with a Megaplus camera model ES 4.0 (patient 1), Hamamatsu Digital Camera model C4742-51-12HR (patient 2), or KeenView high-resolution digital camera using Soft Imaging Solutions AnalySIS ITEM software (patients 3 and 4).
Immunohistochemistry
Immunoperoxidase staining for LC3 (mouse monoclonal antibody, clone 5F10; Nanotools) and p62/ SQSTM1 (guinea pig polyclonal antibody, catalog number GP62-C; Progen Biotechnik) was performed on the formalin-fixed, paraffin-embedded tissue using Ventana Benchmark XT automated slide preparation system at the University of California San Francisco (UCSF) Brain Tumor Research Center Tissue Core. Skeletal muscle from a patient with a documented autophagic vacuolar skeletal myopathy was used as a positive control and normal skeletal muscle as a negative control. Tissue sections (4 to 5 mm thickness) were deparaffinized (EZ-Prep; Ventana Medical Systems) at 751C, followed by antigen retrieval (Cell Conditioning 1; Ventana Medical Systems) at 95 to 1001C. Antibodies were incubated at room temperature for 2 hours, at 1:100 dilutions. Antibody staining was developed using the UltraView Universal DAB detection system (Ventana Medical Systems) and accompanied by hematoxylin counterstain. For comparison, adjacent serial sections were stained with hematoxylin and eosin. Source and anatomic location of all stained sections are listed in Table 1 .
Quantification
Quantification was performed on immunostained sections of formalin-fixed, paraffin-embedded material using a bright-field light microscope. For skeletal muscle samples, we used the approach described previously. 7 For cardiac samples, we modified the protocol slightly to account for the syncytial nature of the myocardium: only cardiomyocytes clearly identifiable as individual cells were included in the final count. Before counting, each slide was viewed under low (Â 2 to Â 20) and high power (Â 40) to determine whether positive fibers were present scarcely or in abundance. A total of 200 fibers/slide was counted in specimens with abundant positivity, whereas a total of 600 fibers/slide was counted in specimens with scarce or patchy positivity (to reduce the sampling error). The tissue on the slide was divided into quadrants, and randomly selected nonoverlapping fields were counted at high power in each quadrant until the total count was reached. The results were recorded as percentages (the number of positive fibers divided by the total number of fibers counted).
Imaging
Images were taken with a DP72 digital camera on a BX41 bright-field light microscope using cellSens Entry 1.4 software (all by Olympus Corp.) and were edited with Adobe Photoshop CS5 Version 12.0.3.
RESULTS
Clinical Histories
Patient 1, a 64-year-old woman with a history of rheumatoid arthritis and chronic renal insufficiency, presented with a 3-month history of progressive muscle weakness involving the lower and upper extremities, chronic dyspnea on exertion, lower extremity edema, and an unintentional 60 lb weight loss. The patient's rheumatoid arthritis had been treated with HCQ for 20 years, most recently at 200 mg/d. The evaluation revealed sick sinus syndrome and paroxysmal atrial fibrillation requiring pacemaker placement, a slightly elevated creatine phosphokinase (CPK) level (269 U/L), unremarkable infectious and neoplastic work-ups, and a myositis pattern on electromyogram. On the basis of a clinical diagnosis of polymyositis, the patient was started on prednisone therapy (60 mg/d; tapered to 20 mg/d over 3 wk); however, her dyspnea, muscle weakness, and lower extremity edema worsened significantly, leading to hospitalization. Diagnostic work-up at this stage demonstrated cardiomegaly and elevated levels of troponin I (5.06 ng/mL), brain natriuretic peptide (>5000 pg/mL), creatinine (1.89 mg/dL), and CPK (545 U/L). A coronary angiogram was normal, whereas a 2-D echocardiogram showed restrictive diastolic filling and moderately increased left ventricular wall thickness concerning for an infiltrative process. The patient underwent endomyocardial and left quadriceps femoris biopsies, both of which showed findings of autophagic vacuolar myopathy consistent with HCQ toxicity. HCQ therapy was discontinued, but the patient's general condition deteriorated with altered mental status, declining renal function, and thrombocytopenia; she died as a result of hypoxic respiratory failure 2 weeks after hospital admission. Clinical features of this case have been described in an earlier report. 10 Patient 2, a 38-year-old woman with a history of ANA-negative discoid lupus erythematosus (treated with CQ [500 mg/d for 7 y]), presented with dizziness, syncopal episodes, progressive bilateral extremity weakness, and decreased muscle mass. The evaluation in a community hospital revealed an elevated CPK level (652 U/L); myopathic features on electromyography; and an intermittent high-grade AV block, congestive heart failure, and a dilated nonischemic cardiomyopathy with abnormal echogenicity suggestive of an infiltrative myocardial disease. A right ventricular biopsy showed interstitial mononuclear inflammation and vacuolar myocardial changes, which were interpreted as artifactual; slides or tissue from this biopsy were not available for review. A rectal biopsy was negative for amyloid deposition. The patient's cardiac condition progressed to third-degree AV block; a pacemaker and a defibrillator were placed and amiodarone started. After a transient 2-week improvement, her cardiac status continued to fluctuate. Two months later, the patient became hypoxic and was admitted to the university hospital, where she died after repeated episodes of cardiorespiratory arrest and resuscitation; CQ treatment was discontinued 5 days before death. Clinical features of this case have been described in an earlier report. 10 Patient 3, a 55-year-old woman with a history of mixed connective tissue disease associated with Sjogren syndrome, Raynaud phenomenon, and mononeuritis multiplex, was referred for evaluation of end-stage liver disease with recurring pleural effusions and ascites; she had been treated with HCQ (400 mg/d) for 6 years. Evaluation revealed a left pleural effusion, ascites, portal hypertension, esophageal varices, a small nodular liver, and splenomegaly. Serologies for hepatitis B, hepatitis C, and HIV were negative, and the patient's liver failure was attributed to autoimmune hepatitis. In preparation for liver transplantation, cardiac and pulmonary function work-ups were performed and revealed normal function in both systems, with the exception of a moderately impaired diffusion capacity (42% of predicted value). Four months later, the patient underwent orthotopic liver transplantation without complications; HCQ was continued at the pretransplantation dose. Two weeks after transplantation, recurrence of bilateral pleural effusions, bilateral lower lobe atelectasis, and ascites necessitated repeat thoracentesis and intubation; the patient remained ventilator dependent during the remainder of her course. Seven weeks after transplantation, she developed progressive renal insufficiency that eventually required dialysis. Brain natriuretic peptide was 1520 pg/mL, and CPK level was 27 U/L. Echocardiogram showed normal left ventricular size and normal systolic function, whereas the right ventricle was moderately dilated and exhibited a severely depressed ejection fraction. Ten weeks after transplantation, repeat echocardiogram showed dilation and hypertrophy of the right ventricle with a severely depressed ejection fraction; blood cultures were positive for Enterococcus faecalis, and the patient died a few days later.
Patient 4, a 75-year-old woman with a history of hypertension and hyperlipidemia, developed an undifferentiated connective tissue disease consisting of lichenoid dermatitis, alopecia, and arthralgia. Her lab work-up showed positive ANA, anticardiolipin and anti-U1-RNP antibodies, negative rheumatoid factor, and negative DS-DNA, SSA, SSB, SM, Jo-1, and Scl-70 antibodies. She responded to HCQ with resolution of the rash and decreased hair loss, so it was continued at 400 mg/d. Five years later, at age 80, the patient developed an acute inferior myocardial infarction and underwent percutaneous transluminal coronary angioplasty, stenting of the proximal right coronary artery, and balloon angioplasty of the posterior descending coronary artery. During this hospitalization, HCQ therapy was discontinued. Six weeks later, the patient underwent elective coronary artery bypass of the left anterior descending and left diagonal coronary arteries. The procedure was well tolerated and free of immediate complications, but the patient died 2 weeks later as a result of aortic dissection.
Cardiac Pathology General Findings
At autopsy, the hearts of patients 1 and 2 showed biventricular hypertrophy (530 g and 430 g, respectively). The heart of patient 3 (407 g) showed moderate right ventricular hypertrophy and dilatation; the left ventricle was grossly unremarkable. In addition, there was mild coronary artery disease (< 50% occlusion) and subacute infectious endocarditis involving the mitral valve. The heart of patient 4 (363 g) showed left ventricular hypertrophy and a healed transmural infarct involving the left ventricular free wall. The right coronary artery stent and the saphenous vein graft to the left diagonal artery were patent, whereas the vein graft to the left anterior descending coronary artery was 50% occluded by a thrombus. In addition, there was dissection of the ascending, transverse, and thoracic segment of the descending aorta.
Features of Autophagic Vacuolar Cardiomyopathy
The hearts of patients 1 to 3 demonstrated prominent cytoplasmic vacuolation of some (patient 3; Fig. 1G ) to nearly all cardiomyocytes (patients 1 and 2; Figs. 1A, D); there was no inflammation, no significant variation in cardiomyocyte diameter or nuclear size and shape, and no fibrosis. Ultrastructurally, there was a marked increase in secondary lysosomes containing electron-dense material, lamellated membrane structures, and curvilinear bodies (Supplemental Digital Content, Figs. S1A-C, http:// links.lww.com/PAS/A163), indicating a disruption in lysosomal function consistent with CQ-induced or HCQinduced autophagic vacuolar cardiomyopathy. In contrast, the heart of patient 4 was microscopically unremarkable except for abundant lipofuscin pigment deposition ( Fig. 1J) and fibrosis in the healed infarct area (not shown); there was no increase in the number of autophagic vacuoles on electron microscopy, but frequent curvilinear bodies, often in the vicinity of lipofuscin granules, were present (not shown).
LC3 and p62 Immunohistochemistry
The hearts of patients 1 to 3 showed abundant LC3 and p62 immunopositivity, primarily in the form of puncta, coarse clusters, and large aggregates in the vicinity of vacuoles ( Fig. 1 ). In the endomyocardial biopsy specimen from patient 1 (Figs. 1B, C) , nearly all cardiomyocytes were LC3 and p62 positive ( Table 2 ). In the autopsy specimen from patient 2, LC3 and p62 staining was patchy at low magnification, with areas of both high (Figs. 1E, F) Table 2 ). A similar patchy pattern of staining was seen in the autopsy specimen from patient 3 (Figs. 2H, I) , but the overall fraction of positive fibers was lower than that in either patient 1 or patient 2 (LC3: 53.2% to 69.8%; p62: 52.5% to 65.3%; Table 2 ). In the autopsy specimen from patient 4, abundant lipofuscin pigment (a type of pigmented autophagic vacuole that accumulates with aging 11 ) showed weak LC3 and p62 positivity (Figs. 1K, L); this background staining was easily distinguishable from the autophagic vacuolar myopathy-associated LC3 and p62 immunopositivity by its distinct green-brown color, perinuclear localization, and well-defined spherical shape of the pigment granules. In this specimen, only rare cardiomyocytes demonstrated coarsely punctate LC3 or p62 staining (LC3: 0.3% to 2.8%; p62: 0.7% to 1.0%; Table 2 ), which was not associated with well-developed vacuolar changes.
Skeletal Muscle Pathology
Features of Autophagic Vacuolar Skeletal Myopathy
Like the hearts, skeletal muscle specimens from patients 1 to 3 showed light microscopic and ultrastructural features of autophagic vacuolar myopathy including fiber vacuolation ( Figs. 2A, D, G) , focal fiber degeneration/regeneration ( Fig. 2A) , and accumulation of autophagic vacuoles and curvilinear bodies (Supplemental Digital Content, Figs. S1D-F, http://links.lww. com/PAS/A163).
LC3 and p62 Immunohistochemistry
Skeletal muscles from patients 1 to 3 (biopsy specimen for patient 1; autopsy specimens for patients 2 and 3) also showed strong LC3 and p62 immunopositivity (Fig. 2) . As previously described in our drug-induced autophagic vacuolar myopathy case series, 7 the staining pattern for both LC3 and p62 was coarsely punctate, coalescing around vacuoles or in the fiber center and running in a linear manner along the longitudinal axis of the fiber (Figs. 2B, C, E, F, H, I) . Interestingly, in all 3 patients the fraction of LC3-positive or p62-positive skeletal muscle fibers was lower than the fraction of LC3positive or p62-positive cardiomyocytes (Table 2) but well above the threshold required for diagnosis of autophagic vacuolar myopathy (defined as 16% LC3-positive fibers and/or 12% p62-positive fibers for 100% specificity 7 ).
DISCUSSION
Currently, definitive pathologic diagnosis of CQ-induced or HCQ-induced autophagic vacuolar cardiomyo-pathy requires electron microscopic identification of welldeveloped autophagic vacuoles and curvilinear bodies. In this study, we demonstrate that immunohistochemistry for LC3 and/or p62 can be used to detect autophagosome accumulation by light microscopy, thus providing a valuable diagnostic tool that can be used even by pathology laboratories without easy access to an electron microscope. The 4 patients included in our study were all women with a history of rheumatologic and/or connective tissue disease who were treated with CQ or HCQ for 5 to 20 years. Patients 1 to 3 were diagnosed with autophagic vacuolar myopathy either premortem (patient 1) or postmortem (patients 2 and 3); patient 4 (drug-treated control) was treated with HCQ but showed no evidence of vacuolar change in the heart (Fig. 1J) . It is noteworthy that HCQ treatment of patient 4 was discontinued 8 wk before death; however, given that CQ and HCQ have a half-life of 40 to 50 d and can persist in the skin for even longer time periods, 4, 12, 13 it is reasonable to assume that patient 4 was exposed to a significant level of circulating HCQ at the time of her death-an assumption supported by the presence of curvilinear bodies in the heart (not shown). The 3 patients with autophagic vacuolar cardiomyopathy showed a very high degree of cardiac LC3 and p62 immunopositivity (50% to 100%; Fig. 1   FIGURE 2 . Histology and LC3 and p62 immunohistochemistry in skeletal muscle sections. A, D, and G, Hematoxylin and eosinstained sections from patient 1 (A), patient 2 (section S1; D), and patient 3 (G) show degenerating/regenerating muscle fibers (A) and mild (A and D) to prominent (G) fiber vacuolation. B, C, E, F, H, and I, LC3 and p62 staining is finely to coarsely punctate, associated with vacuoles, and most often localized in the fiber center, aligned with the longitudinal fiber axis. Scale bar, 100 mM. Localization of individual tissue sections is shown in Table 1 . For patient 3, each cardiac section included 2 different anatomic areas (C1: RV and septum; C2: LV and septum), both of which showed a similar degree of LC3 and p62 labeling; the percentages shown in the table are averages for all tissue on the slide. Skeletal muscle LC3 and p62 labeling could not be evaluated for patient 4, whose autopsy was restricted by the patient's family to the heart, lungs, and aorta. LV indicates left ventricle; RV, right ventricle. and Table 2 ); in contrast, only a minimal degree of staining was present in the heart of patient 4 (0% to 3%; Fig. 1 and Table 2 ). The number of cases we studied is too small to allow calculation of sensitivity and specificity for different percentages of LC3-immunopositive and/or p62-immunopositive cardiomyocytes. However, given that almost no cardiomyocytes were LC3 or p62 positive in the HCQ-treated patient with a nonmyopathic heart (patient 4), our data indicate that LC3 and/or p62 immunohistochemistry can be used as a qualitative (yes/no) screening test for autophagic vacuolar cardiomyopathy; in cases with borderline immunopositivity, the diagnosis can be confirmed by subsequent electron microscopy.
In the 2 autopsy cases in our series (patients 2 and 3), immunopositivity for both LC3 and p62 was patchy, with high-staining and low-staining areas often present side by side on the same slide (eg, compare Figs. 2D-F with supplemental Fig. S2 , http://links.lww.com/PAS/ A164; both sets of images were taken from the same section of the interventricular septum). High-power examination showed that nearly all vacuolated cardiomyocytes were LC3 or p62 positive even in low-staining areas, with faint staining being the result of a low number of stained puncta, presumably autophagosomes, in each cell (Supplemental Digital Content, Fig. S2 , http://links. lww.com/PAS/A164). On a small biopsy sample, such low positivity areas could represent a diagnostic challenge; thus, sampling several nonadjacent endomyocardial sites may improve the diagnostic accuracy. Notably, however, the overall fraction of LC3-positive or p62-positive cardiomyocytes was remarkably similar among different anatomic regions of the same heart (Tables 1, 2), suggesting that the exact location of the biopsy site is not critical for the diagnosis.
In all 3 autophagic vacuolar cardiomyopathy cases examined in the current study, the degree of LC3 and p62 immunopositivity was considerably higher in the patients' hearts than in their skeletal muscles ( Table 2 ). (For patient 4, the autopsy was restricted to the heart, lungs, and aorta by the patient's family; thus, skeletal muscle was not available for analysis.) Given that treatment with CQ or HCQ leads to neuromyotoxicity more commonly than cardiotoxicity, this may represent ascertainment bias (mild cardiac involvement may stay asymptomatic and thus unrecognized in nonfatal cases of CQ or HCQ toxicity). Nonetheless, all 3 patients met the diagnostic criteria for autophagic vacuolar skeletal myopathy. 7 Thus, in a CQ-treated or HCQ-treated patient with cardiac symptoms and features of autophagic vacuolar myopathy on skeletal muscle biopsy, it would be clinically reasonable to attribute the heart disease to drug toxicity and discontinue the treatment on empirical basis. Definitive diagnosis, however, would require an endomyocardial biopsy. Regardless of the type of tissue sampled, the use of LC3 and/ or p62 immunohistochemistry will facilitate the diagnostic process by decreasing the turn-around time, cost, and sampling error associated with ultrastructural studies. 7 LC3 (or microtubule-associated protein 1 light chain 3) is an autophagy regulatory protein that binds autophagic membranes in its lipidated (LC3-II) form, which is preferentially detected by immunohistochemistry. p62/SQSTM1, an adapter protein that binds LC3-II and targets ubiquitinated protein aggregates for lysosomal degradation, is selectively degraded by autophagy. Thus, accumulation of LC3-II-labeled autophagosomes and/or p62 aggregates is a robust marker of autophagic flux inhibition at any point beyond autophagosome formation. 14 However, cardiac autophagosome build-up is not specific for CQ-induced or HCQ-induced toxicity and can also be observed in inherited autophagic cardiomyopathies such as Danon disease and acid maltase deficiency (Pompe disease). 15 Thus, the clinical context (patient's age, family history, and medication history) has to be taken into account to properly interpret cardiomyocyte vacuolation associated with a high degree of LC3 and/or p62 immunopositivity. In ambiguous cases, however, ultrastructural identification of curvilinear bodies (Supplemental Digital Content, Fig. S1 , http:// links.lww.com/PAS/A163) would corroborate CQ or HCQ toxicity as the cause of autophagy impairment and autophagosome accumulation.
For patients 1 and 2, autophagic vacuolar cardiomyopathy was the sole cause of death. In contrast, patient 3 had several other comorbid conditions (renal microangiopathy, splenic infarcts, and subacute infectious endocarditis) that contributed to her death. In this context, it is interesting (1) that echocardiography showed evidence of an infiltrative process only in patients 1 and 2 but not in patient 3, and (2) that both cardiomyocyte vacuolation and the degree of LC3 and p62 positivity were significantly higher in the hearts of patients 1 and 2 (80% to 100% range) than in the heart of patient 3 (50% to 60% range). These data suggest that the heart has a large functional reserve, with heart failure developing only when almost the entire myocardium develops prominent accumulation of autophagic debris. However, additional work will be required to establish whether this observation holds true for most cases of autophagic vacuolar cardiomyopathy.
In summary, CQ-induced or HCQ-induced autophagic vacuolar cardiomyopathy is not universally fatal-cardiac function can sometimes be regained after the drug is discontinued 1,6 -but early recognition of this complication requires a high degree of clinical suspicion and accurate pathologic diagnosis. In the current study, we show that immunohistochemistry for autophagic markers LC3 and/or p62 can be used to detect myocardial autophagosome accumulation by light microscopy. By lowering the barrier to accurate diagnosis (vacuolar changes seen on routine histology can appear nonspecific, and electron microscopy is not always possible), the availability of these immunohistochemical markers will decrease the number of misdiagnosed patients and thus result in significant improvement in health care outcomes.
